<?xml version="1.0" encoding="UTF-8"?><rss xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:atom="http://www.w3.org/2005/Atom" version="2.0"><channel><title><![CDATA[RichStorm]]></title><description><![CDATA[RichStorm LLC]]></description><link>https://www.richstorm.co/blog</link><generator>RSS for Node</generator><lastBuildDate>Fri, 15 May 2026 09:48:18 GMT</lastBuildDate><atom:link href="https://www.richstorm.co/blog-feed.xml" rel="self" type="application/rss+xml"/><item><title><![CDATA[The Quiet Art of the Weekend Investor]]></title><description><![CDATA[How slowing down might be the smartest move you ever make Prepared by Richstorm.co   There is a particular kind of Saturday morning that every investor knows. The coffee is warm, the house is still, and somewhere between the second cup and the rustling of a newspaper, a quiet thought arrives: How are my investments doing? No bells. No tickers flashing red or green. Just you, your thoughts, and the unhurried luxury of time. This is the world of the weekend investor — and it is, perhaps, one of...]]></description><link>https://www.richstorm.co/post/the-quiet-art-of-the-weekend-investor</link><guid isPermaLink="false">6a0506aa618ba45174004aa7</guid><pubDate>Wed, 13 May 2026 23:25:27 GMT</pubDate><enclosure url="https://static.wixstatic.com/media/nsplsh_954e1eb975ed4ac1b7b369a81728802d~mv2.jpg/v1/fit/w_1000,h_1000,al_c,q_80/file.png" length="0" type="image/png"/><dc:creator> Ting C.</dc:creator></item><item><title><![CDATA[The Global Energy Transition: US, China &#38; EU: A 40-Year Arc]]></title><description><![CDATA[A data-driven comparison of electricity generation mixes, national clean energy plans, and the wind &#38; solar buildout to 2055   Prepared by Richstorm.co   Executive Summary   The electricity systems of the United States, China, and the European Union are undergoing their most profound transformation since the 20th century. Coal — the foundation of industrial-era power — is in structural decline across all three blocs. Wind and solar are ascending to become the dominant source of electricity...]]></description><link>https://www.richstorm.co/post/the-global-energy-transition-us-china-eu-a-40-year-arc</link><guid isPermaLink="false">69fe4ceb4f7ebdc9f6ab0d9a</guid><pubDate>Fri, 08 May 2026 20:59:14 GMT</pubDate><enclosure url="https://static.wixstatic.com/media/nsplsh_4e6e6e324463366e695655~mv2_d_4239_2815_s_4_2.jpg/v1/fit/w_1000,h_1000,al_c,q_80/file.png" length="0" type="image/png"/><dc:creator> Ting C.</dc:creator></item><item><title><![CDATA[Will China Dominate Rare Earths—Like the Middle East Dominated Oil?]]></title><description><![CDATA[Prepared by Richstorm.co The numbers already look familiar. The geopolitical playbook already looks familiar. The question is whether the world is making the same mistakes it made with oil — and whether there is still time to avoid them. In the 1970s, the world learned what it meant to be structurally dependent on a resource controlled by a small number of adversarial states. Oil embargoes, price shocks, and geopolitical leverage reshaped economies overnight. Fifty years later, the same...]]></description><link>https://www.richstorm.co/post/will-china-dominate-rare-earths-like-the-middle-east-dominated-oil</link><guid isPermaLink="false">69fe0109ecab901137512506</guid><pubDate>Fri, 08 May 2026 15:31:38 GMT</pubDate><enclosure url="https://static.wixstatic.com/media/9c0fb3338ad146beb45f0990099c0501.jpg/v1/fit/w_507,h_337,al_c,q_80/file.png" length="0" type="image/png"/><dc:creator> Ting C.</dc:creator></item><item><title><![CDATA[AI Will Win: How To Build It To Last]]></title><description><![CDATA[Prepared by Richstorm.co AI dominance across critical industries is no longer a prediction. It is an irreversible trajectory. The only meaningful question left is whether we build the scaffolding to make failure survivable — before a failure makes that question urgent.   Here is the honest tension at the heart of this entire series: knowing everything we now understand about AI dependency and failure modes — it does not change what happens next. AI will dominate these industries regardless....]]></description><link>https://www.richstorm.co/post/ai-will-win-how-to-build-it-to-last</link><guid isPermaLink="false">69fded6520805f9d8a866d92</guid><pubDate>Fri, 08 May 2026 14:09:11 GMT</pubDate><enclosure url="https://static.wixstatic.com/media/nsplsh_91a7187150294d849efc8c1f31c859a2~mv2.jpg/v1/fit/w_1000,h_1000,al_c,q_80/file.png" length="0" type="image/png"/><dc:creator> Ting C.</dc:creator></item><item><title><![CDATA[Can We Go Back? Why pre-AI normal is already gone for some industries]]></title><description><![CDATA[Prepared by Richstorm.co If AI infrastructure failed tomorrow, could hospitals go back to purely human diagnostics? Could financial markets return to human-paced trading? The answer, for the sectors most deeply affected, is: not cleanly, not quickly, and in some cases not at all. It is a natural question. If AI fails — through a cyberattack, a geopolitical rupture, or a regulatory emergency — could affected industries simply revert? Could we go back to the way things were, even briefly, while...]]></description><link>https://www.richstorm.co/post/can-we-go-back-why-pre-ai-normal-is-already-gone-for-some-industries</link><guid isPermaLink="false">69fdeb115bf92805eb5fa88a</guid><pubDate>Fri, 08 May 2026 14:01:32 GMT</pubDate><enclosure url="https://static.wixstatic.com/media/nsplsh_8d8c47c1d9a44dd9abd79b65348eb49e~mv2.jpg/v1/fit/w_1000,h_1000,al_c,q_80/file.png" length="0" type="image/png"/><dc:creator> Ting C.</dc:creator></item><item><title><![CDATA[Five Ways AI Infrastructure Could Actually Fall]]></title><description><![CDATA[Prepared by Richstorm.co We spend a lot of time talking about what AI will do when it works. We spend almost no time on what happens when it doesn't. That asymmetry is itself a risk. Every major infrastructure technology in history has eventually failed — electricity, telecommunications, financial systems — and in each case, the failure was more damaging because society had not seriously planned for it. AI is no different. Here are the five most credible paths to a large-scale AI...]]></description><link>https://www.richstorm.co/post/five-ways-ai-infrastructure-could-actually-fall</link><guid isPermaLink="false">69fddf18ecab90113750c78a</guid><pubDate>Fri, 08 May 2026 13:24:23 GMT</pubDate><enclosure url="https://static.wixstatic.com/media/nsplsh_725346784247706e6c7577~mv2_d_5915_3949_s_4_2.jpg/v1/fit/w_1000,h_1000,al_c,q_80/file.png" length="0" type="image/png"/><dc:creator> Ting C.</dc:creator></item><item><title><![CDATA[What Breaks When AI Goes Dark: Industries on the Edge of AI Dependency — and What Happens When the Infrastructure Fails]]></title><description><![CDATA[Prepared by Richstorm.co Executive Summary A new and largely invisible layer of critical infrastructure has taken shape over the past decade: artificial intelligence. Where previous generations of critical infrastructure — power grids, telecommunications, financial rails — were built with redundancy, regulatory oversight, and disaster recovery protocols, AI infrastructure has grown at a pace that has outrun institutional caution.   This report identifies eight industries that are converging...]]></description><link>https://www.richstorm.co/post/what-breaks-when-ai-goes-dark-industries-on-the-edge-of-ai-dependency-and-what-happens-when-the-i</link><guid isPermaLink="false">69fdd7447bccf7fb9df642ef</guid><pubDate>Fri, 08 May 2026 12:35:22 GMT</pubDate><enclosure url="https://static.wixstatic.com/media/nsplsh_415cfca1f7a54ec5a381f22359d45c94~mv2.jpg/v1/fit/w_1000,h_1000,al_c,q_80/file.png" length="0" type="image/png"/><dc:creator> Ting C.</dc:creator></item><item><title><![CDATA[The Rare Earth Risk That AI Investors Are Ignoring: How China's Export Controls Threaten the AI Infrastructure Supply Chain — And What It Means for Your Portfolio]]></title><description><![CDATA[Prepared by Richstorm.co Executive Summary The AI infrastructure investment thesis is well known: semiconductor companies, cloud hyperscalers, and data center infrastructure providers are the picks-and-shovels beneficiaries of the most significant technology buildout in history. What is far less discussed — and almost entirely absent from mainstream financial coverage — is the rare earth supply chain vulnerability that sits underneath every layer of that infrastructure. China controls 85 to...]]></description><link>https://www.richstorm.co/post/the-rare-earth-risk-that-ai-investors-are-ignoring-how-china-s-export-controls-threaten-the-ai-infr</link><guid isPermaLink="false">69fd2e8aff1f3255572b8d8b</guid><pubDate>Fri, 08 May 2026 00:39:46 GMT</pubDate><enclosure url="https://static.wixstatic.com/media/nsplsh_463142302d697541784f34~mv2_d_4364_2910_s_4_2.jpg/v1/fit/w_1000,h_1000,al_c,q_80/file.png" length="0" type="image/png"/><dc:creator> Ting C.</dc:creator></item><item><title><![CDATA[Investment Scenario Analysis: Eli Lilly (LLY) and Summit Therapeutics (SMMT) Benchmarked Against the S&#38;P 500 Index]]></title><description><![CDATA[Prepared by Richstorm.co     Purpose of This Report This report summarizes a scenario analysis comparing two pharmaceutical investment opportunities — Eli Lilly (LLY) and Summit Therapeutics (SMMT) — against the S&#38;P 500 index as a benchmark across one-year, two-year, and five-year time horizons. The analysis is illustrative and educational in nature. It is designed to demonstrate the range of possible outcomes across different investment types — a large-cap pharma platform company, a...]]></description><link>https://www.richstorm.co/post/investment-scenario-analysis-eli-lilly-lly-and-summit-therapeutics-smmt-benchmarked-against-the</link><guid isPermaLink="false">69fd121b4f7ebdc9f6a7ba1a</guid><pubDate>Thu, 07 May 2026 22:44:05 GMT</pubDate><enclosure url="https://static.wixstatic.com/media/nsplsh_10e8bc07a16947aca1be83ee7e641314~mv2.jpg/v1/fit/w_1000,h_1000,al_c,q_80/file.png" length="0" type="image/png"/><dc:creator> Ting C.</dc:creator></item><item><title><![CDATA[Tech vs. Pharma: Why Technology Leads S&#38;P 500 Growth — And What It Means for Investors]]></title><description><![CDATA[A Structural Comparison of Two Sectors With Fundamentally Different Value Creation Economics Prepared by richstorm.co •  May 2026   The Question Every Pharma Investor Eventually Asks Over long time horizons, the technology sector has consistently outpaced the S&#38;P 500, generated the largest market capitalizations in history, and rewarded patient investors with compounding returns that no other sector has matched at scale. Pharmaceutical companies, meanwhile, develop drugs that save lives,...]]></description><link>https://www.richstorm.co/post/tech-vs-pharma-why-technology-leads-s-p-500-growth-and-what-it-means-for-investors</link><guid isPermaLink="false">69f9cbf1438dc58e2c8ba47c</guid><pubDate>Tue, 05 May 2026 10:55:41 GMT</pubDate><enclosure url="https://static.wixstatic.com/media/nsplsh_4555735677454f73626c45~mv2_d_7360_4912_s_4_2.jpg/v1/fit/w_1000,h_1000,al_c,q_80/file.png" length="0" type="image/png"/><dc:creator> Ting C.</dc:creator></item><item><title><![CDATA[How to Research Pharma Companies Like an Analyst: A Complete Guide to Public Information Sources for Serious Pharmaceutical Investors]]></title><description><![CDATA[Prepared by richstorm.co •  May 2026   The Information Advantage Most Investors Don't Know They Have A persistent assumption among retail investors is that sophisticated pharmaceutical analysis requires Bloomberg terminals, proprietary databases, Wall Street research subscriptions, or insider connections. This assumption is wrong — and it is costing investors the analytical edge that serious, methodical research could give them. The raw material for genuinely rigorous pharmaceutical...]]></description><link>https://www.richstorm.co/post/how-to-research-pharma-companies-like-an-analyst-a-complete-guide-to-public-information-sources-for</link><guid isPermaLink="false">69f4df9d8c5a662f219ad761</guid><pubDate>Fri, 01 May 2026 17:20:49 GMT</pubDate><enclosure url="https://static.wixstatic.com/media/nsplsh_82ea7c2a59794e1fa17da9dd7ac3cf5b~mv2.jpg/v1/fit/w_1000,h_1000,al_c,q_80/file.png" length="0" type="image/png"/><dc:creator> Ting C.</dc:creator></item><item><title><![CDATA[Who Really Decides What Gets Built in Big Pharma? The Decision-Making Architecture Behind Pharmaceutical Platform Strategy]]></title><description><![CDATA[Prepared by richstorm.co    The Question Most Investors Never Ask When a pharmaceutical company announces a major pipeline commitment — entering a new therapeutic area, adopting a new drug-delivery technology, or making a multi-billion dollar acquisition — the public narrative is almost always structured around the CEO. The press release quotes the CEO. The analyst calls direct questions to the CEO. The financial media attributes the decision to the CEO's vision. This framing is both...]]></description><link>https://www.richstorm.co/post/who-really-decides-what-gets-built-in-big-pharma-the-decision-making-architecture-behind-pharmaceut</link><guid isPermaLink="false">69f4c1cc88651042cd16ac58</guid><pubDate>Fri, 01 May 2026 15:40:24 GMT</pubDate><enclosure url="https://static.wixstatic.com/media/nsplsh_de247f9e00af413faacb4906fd523988~mv2.jpg/v1/fit/w_1000,h_1000,al_c,q_80/file.png" length="0" type="image/png"/><dc:creator> Ting C.</dc:creator></item><item><title><![CDATA[The CEOs Behind the Pipelines: Leadership, Background &#38; What Makes a Successful Pharma CEO]]></title><description><![CDATA[Covering: LLY · AZN · ABBV · MRK · JNJ · AMGN · NVO · PFE Prepared by richstorm.co •  May 2026   The Right Question About Pharma Leadership A common claim in financial media is that large company performance depends primarily on the CEO. In most industries this is partially true. In pharmaceuticals, the relationship is more complicated — and more interesting. Drug pipelines take 10 to 15 years to develop. A CEO who takes office today will spend most of their tenure commercializing drugs that...]]></description><link>https://www.richstorm.co/post/the-ceos-behind-the-pipelines-leadership-background-what-makes-a-successful-pharma-ceo</link><guid isPermaLink="false">69f4b4a088651042cd168e0f</guid><pubDate>Fri, 01 May 2026 14:18:26 GMT</pubDate><enclosure url="https://static.wixstatic.com/media/nsplsh_9c9945cd6d924119ad18822c41f20cf8~mv2.jpg/v1/fit/w_1000,h_1000,al_c,q_80/file.png" length="0" type="image/png"/><dc:creator> Ting C.</dc:creator></item><item><title><![CDATA[Do Mega-Cap Pharma Companies Compete With Each Other?]]></title><description><![CDATA[A Framework for Understanding Pharmaceutical Competition Prepared by richstorm.co •  May 2026   The Question Investors Get Wrong A common analytical shortcut in pharmaceutical sector investing is to treat large-cap pharma companies as a monolithic competitive group — as if Eli Lilly, AstraZeneca, AbbVie, and Novo Nordisk are all fighting for the same patients, the same prescriptions, and the same revenue pool. The reality is far more nuanced. Yes, these companies compete — but the nature,...]]></description><link>https://www.richstorm.co/post/do-mega-cap-pharma-companies-compete-with-each-other</link><guid isPermaLink="false">69f4a55fb7104c93b99cb675</guid><pubDate>Fri, 01 May 2026 13:13:15 GMT</pubDate><enclosure url="https://static.wixstatic.com/media/nsplsh_304cdcb28d6f4fb0acceda0254757380~mv2.jpg/v1/fit/w_1000,h_1000,al_c,q_80/file.png" length="0" type="image/png"/><dc:creator> Ting C.</dc:creator></item><item><title><![CDATA[Mega-Cap Pharma Pipeline Differentiation: What Each Company Is Building — And Why It Matters]]></title><description><![CDATA[Covering: LLY · AZN · ABBV · MRK · JNJ · AMGN · NVO · PFE   Prepared by richstorm.co •  May 2026 Executive Summary Pipeline differentiation is the single most important long-term driver of value in pharmaceutical sector investing. Which diseases a company targets, which scientific mechanisms it uses, and which technology platforms it builds around determine revenue sustainability far more than any near-term earnings beat or miss. This report analyzes the pipeline positioning of eight leading...]]></description><link>https://www.richstorm.co/post/mega-cap-pharma-pipeline-differentiation-what-each-company-is-building-and-why-it-matters</link><guid isPermaLink="false">69f4a09c7b1c42fb24f28cb6</guid><pubDate>Fri, 01 May 2026 12:53:14 GMT</pubDate><enclosure url="https://static.wixstatic.com/media/nsplsh_91d4bd4d4341466791d5b478efeaefb0~mv2.jpg/v1/fit/w_1000,h_1000,al_c,q_80/file.png" length="0" type="image/png"/><dc:creator> Ting C.</dc:creator></item><item><title><![CDATA[Beyond the ETF: Five Niches Where Biotech Beats the S&#38;P 500]]></title><description><![CDATA[Why biotech ETFs underperform — and where the real edge lives Prepared by richstorm.co •  May 2026 1. THE PARADOX — ETFS UNDERPERFORM, YET THE EDGE EXISTS Our analysis across this research series has reached a conclusion that initially appears contradictory: biotech ETFs — the most accessible way for retail investors to gain biotech exposure — have underperformed the S&#38;P 500 over both 5-year and 10-year periods, with far greater volatility. Yet sophisticated investors continue to allocate...]]></description><link>https://www.richstorm.co/post/beyond-the-etf-five-niches-where-biotech-beats-the-s-p-500</link><guid isPermaLink="false">69f48f608ca39cf305c5f903</guid><pubDate>Fri, 01 May 2026 11:34:16 GMT</pubDate><enclosure url="https://static.wixstatic.com/media/nsplsh_f9bf209a10934253aeab658968ca8756~mv2.jpg/v1/fit/w_1000,h_1000,al_c,q_80/file.png" length="0" type="image/png"/><dc:creator> Ting C.</dc:creator></item><item><title><![CDATA[Biotech ETF Deep Dive: Composition, Returns &#38; Investor Fit]]></title><description><![CDATA[Covering: XBI  ·  IBB  ·  ARKG  ·  BBH Prepared by richstorm.co •  April 2026 1. WHY BIOTECH ETFS? THE INVESTMENT CASE For most retail investors, biotech ETFs represent the most practical entry point into small and mid-cap pharmaceutical investing. Individual biotech stock-picking requires scientific expertise, access to clinical trial data, and the stomach to hold through 50-90% binary-event drawdowns. ETFs solve the diversification problem: rather than betting on a single clinical outcome,...]]></description><link>https://www.richstorm.co/post/biotech-etf-deep-dive-composition-returns-investor-fit</link><guid isPermaLink="false">69f20ac5d3f2ae6dd916e80a</guid><pubDate>Wed, 29 Apr 2026 13:43:37 GMT</pubDate><enclosure url="https://static.wixstatic.com/media/nsplsh_9ec872ecf1ca41898ae1e8979f9e78a1~mv2.jpg/v1/fit/w_1000,h_1000,al_c,q_80/file.png" length="0" type="image/png"/><dc:creator> Ting C.</dc:creator></item><item><title><![CDATA[Pharmaceutical Sector Investing: Mega-Cap vs. Small/Mid-Cap]]></title><description><![CDATA[Strategies, Analysis &#38; Exit Frameworks Prepared by richstorm.co •  April 2026 1. EXECUTIVE SUMMARY This report synthesizes a comprehensive analysis of pharmaceutical sector investing, covering three interconnected topics: (1) the performance characteristics and analytical frameworks for mega-cap versus small and mid-cap pharma companies; (2) practical strategies for retail investors seeking exposure to smaller pharma names; and (3) a structured framework for exiting these investments across...]]></description><link>https://www.richstorm.co/post/pharmaceutical-sector-investing-mega-cap-vs-small-mid-cap</link><guid isPermaLink="false">69f201f524f9d3e5cd7307a0</guid><pubDate>Wed, 29 Apr 2026 13:08:13 GMT</pubDate><enclosure url="https://static.wixstatic.com/media/nsplsh_68c635ecff794c65a2e109bfda8df9cd~mv2.jpg/v1/fit/w_1000,h_1000,al_c,q_80/file.png" length="0" type="image/png"/><dc:creator> Ting C.</dc:creator></item><item><title><![CDATA[Mega-Cap Pharma Sector Analysis: Performance, Drivers &#38; Forward Outlook]]></title><description><![CDATA[Covering: LLY  ·  AZN  ·  ABBV  ·  MRK  ·  JNJ  ·  AMGN  ·  NVO  ·  PFE   Prepared by richstorm.co •  April 2026 EXECUTIVE SUMMARY This report analyzes the stock performance of the eight largest pharmaceutical companies by market capitalization — Eli Lilly (LLY), AstraZeneca (AZN), AbbVie (ABBV), Merck (MRK), Johnson &#38; Johnson (JNJ), Amgen (AMGN), Novo Nordisk (NVO), and Pfizer (PFE) — across three time horizons: trailing 12 months, 5 years, and 10 years, benchmarked against the S&#38;P 500.  ...]]></description><link>https://www.richstorm.co/post/mega-cap-pharma-sector-analysis-performance-drivers-forward-outlook</link><guid isPermaLink="false">69ee563ccf2afc83b04f091d</guid><pubDate>Sun, 26 Apr 2026 18:21:45 GMT</pubDate><enclosure url="https://static.wixstatic.com/media/nsplsh_7077634b46374c342d6e6f~mv2_d_5184_3456_s_4_2.jpg/v1/fit/w_1000,h_1000,al_c,q_80/file.png" length="0" type="image/png"/><dc:creator> Ting C.</dc:creator></item><item><title><![CDATA[Sector Comparison Report: AI / Technology vs. Pharmaceutical Sectors]]></title><description><![CDATA[Investment Outlook for the Next Decade Prepared by richstorm.co •  April 2026 Executive Summary   Both the Artificial Intelligence / Technology sector and the Pharmaceutical sector represent legitimate, decade-long secular investment themes — yet they differ fundamentally in how they generate returns, the nature of their risks, and the investor profiles they best serve. This report provides a comprehensive, dimension-by-dimension comparison drawing on live market data as of April 2026 and...]]></description><link>https://www.richstorm.co/post/sector-comparison-report-ai-technology-vs-pharmaceutical-sectors</link><guid isPermaLink="false">69edfd837c7678baade80579</guid><pubDate>Sun, 26 Apr 2026 12:08:02 GMT</pubDate><enclosure url="https://static.wixstatic.com/media/nsplsh_a42a6803480f44d785433686e9d0c6d2~mv2.jpg/v1/fit/w_1000,h_1000,al_c,q_80/file.png" length="0" type="image/png"/><dc:creator> Ting C.</dc:creator></item></channel></rss>